Evidence map›Paper›PMID 42583940›Full record

Trial reportJournal of comparative effectiveness research2026

Matching-adjusted indirect comparison of fruquintinib versus ramucirumab in advanced gastric or gastroesophageal junction adenocarcinoma.

Nan An, Jiaying Chen, Jibin Li, Lin Shen, Weijian Guo, Tianshu Liu, Jin Li, Shukui Qin, Yuxian Bai, Zhendong Chen and 4 more

Abstract readComparative StudyRandomized Controlled TrialClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of comparative effectiveness research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Nan AnDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.ORCID 0009-0001-6240-4719
Jiaying ChenDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.
Jibin LiDepartment of Clinical Research, Sun Yat-sen University Cancer Center, Guangzhou, China.
Lin ShenDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Weijian GuoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Tianshu LiuDepartment of Oncology, Zhongshan Hospital Fudan University, Shanghai, China.
Jin LiDepartment of Oncology, Shanghai Gobroad Cancer Hospital, China Pharmaceutical University, Shanghai, China.
Shukui QinDepartment of Medical Oncology, Nanjing Tianyinshan Cancer Hospital of China Pharmaceutical University (CPU), Nanjing, China.
Yuxian BaiDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Haerbin, China.
Zhendong ChenDepartment of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Jufeng WangDepartment of Oncology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Yueyin PanDepartment of Chemotherapy Oncology, Anhui Provincial Hospital, Hefei, China.
Ruihua XuDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.
Feng WangDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdenocarcinomaAntibodies, Monoclonal, HumanizedBenzofuransEsophageal NeoplasmsQuinazolinesRamucirumabStomach NeoplasmsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsEsophagogastric JunctionFemaleHumansMaleMiddle AgedPaclitaxelAntibodies, Monoclonal, HumanizedBenzofuransHMPL-013PaclitaxelQuinazolinesRamucirumabadvanced cancerfruquintinibgastric cancergastroesophageal junction adenocarcinomaMAICmatching-adjusted indirect comparisonramucirumab

Identifiers

PMID42583940
PMCPMC13556922

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.